ELAB
Health Care

Elevai Labs, Inc.

ELAB
Since

Headquarters:

CA, United States

Exchange:

NASDAQ

Industry:

Biotechnology

Number of Employees:

18.00

Current Fiscal Year:

2024

Market Cap:

7.04M

Price per Share:

$2.29

Quarterly Dividend per Share:

Year-to-date Performance:
-86.8088%
Dividend Yield:
%
Price-to-book Ratio:
0.82
Trailing P/E Ratio:
N/A

Price History

Latest Prices

DateOpenHighLowClose
2025-04-302.342.452.142.29
2025-04-292.352.412.252.34
2025-04-282.282.37952.162.28
2025-04-252.262.712.212.26
2025-04-242.932.952.152.22

Elevai Labs Inc., a skincare development company, designs, manufactures, and markets skincare products in the United States. The company offers Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. It serves dermatologists, plastic surgeons, medical spa owners, and physicians focused on aesthetic and therapeutic skincare. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs Inc. was incorporated in 2020 and is based in Newport Beach, California.

Financial Performance

2024 Revenue:2.45M

Detailed view of quarterly revenue

2024 Net Income:-5.47M

Detailed view of quarterly net income

2024 Free Cash Flow:-6.05M

Overview of free cash flow for the quarter

Annual Revenue Comparison

Compares total annual revenues

Similar Companies

Health Care
ELUT
Elutia Inc.
Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
69.87M
Market Cap
*Data based on the last 12 months.